DK1384726T3 - Immunoterapeutiske kombinationer til behandling af tumorer, der overudtrykker gangliosider - Google Patents

Immunoterapeutiske kombinationer til behandling af tumorer, der overudtrykker gangliosider

Info

Publication number
DK1384726T3
DK1384726T3 DK02759751T DK02759751T DK1384726T3 DK 1384726 T3 DK1384726 T3 DK 1384726T3 DK 02759751 T DK02759751 T DK 02759751T DK 02759751 T DK02759751 T DK 02759751T DK 1384726 T3 DK1384726 T3 DK 1384726T3
Authority
DK
Denmark
Prior art keywords
gangliosides
treat tumors
tumors overexpressing
immunotherapeutic combinations
immunotherapeutic
Prior art date
Application number
DK02759751T
Other languages
English (en)
Inventor
Del Calvo Adriana Maria Rojas
Lepez Ana Maria Vazquez
Rodriguez Yildian Diaz
Fernandez Mauro A Alfonso
Molina Luis Enrique Fernandez
Rodriguez Rolando Perez
Gonz0Lez Alexis Perez
Perez Adriana Carr
Original Assignee
Centro Inmunologia Molecular
Molina Luis Enrique Fernandez
Vazquez Lopez Ana Maria
Perez Rodriguez Roland
Perez Gonzalez Alexis
Perez Adriana Carr
Dyaz Rodryguez Yildian
Fernandez Mauro A Alfonso
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular, Molina Luis Enrique Fernandez, Vazquez Lopez Ana Maria, Perez Rodriguez Roland, Perez Gonzalez Alexis, Perez Adriana Carr, Dyaz Rodryguez Yildian, Fernandez Mauro A Alfonso filed Critical Centro Inmunologia Molecular
Application granted granted Critical
Publication of DK1384726T3 publication Critical patent/DK1384726T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK02759751T 2001-04-06 2002-04-08 Immunoterapeutiske kombinationer til behandling af tumorer, der overudtrykker gangliosider DK1384726T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2001008420010084A CU23007A1 (es) 2001-04-06 2001-04-06 Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
PCT/CU2002/000002 WO2002081661A2 (es) 2001-04-06 2002-04-08 Combinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos

Publications (1)

Publication Number Publication Date
DK1384726T3 true DK1384726T3 (da) 2008-12-15

Family

ID=40291118

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02759751T DK1384726T3 (da) 2001-04-06 2002-04-08 Immunoterapeutiske kombinationer til behandling af tumorer, der overudtrykker gangliosider
DK02759752T DK1411064T3 (da) 2001-04-06 2002-04-08 Gangliosid-associerede rekombinante antistoffer og anvendelsen deraf i diagnosen og behandlingen af tumorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK02759752T DK1411064T3 (da) 2001-04-06 2002-04-08 Gangliosid-associerede rekombinante antistoffer og anvendelsen deraf i diagnosen og behandlingen af tumorer

Country Status (37)

Country Link
US (3) US20050069535A1 (da)
EP (3) EP1384726B1 (da)
JP (2) JP4366080B2 (da)
KR (3) KR100863509B1 (da)
CN (3) CN101054417B (da)
AR (2) AR033123A1 (da)
AT (3) ATE477279T1 (da)
AU (3) AU2002308348B2 (da)
BG (2) BG66293B1 (da)
BR (3) BR0208676B1 (da)
CA (2) CA2443372C (da)
CU (1) CU23007A1 (da)
CZ (2) CZ296276B6 (da)
DE (2) DE60223547T2 (da)
DK (2) DK1384726T3 (da)
EA (2) EA006936B1 (da)
EC (2) ECSP034788A (da)
ES (2) ES2296986T3 (da)
HK (3) HK1066818A1 (da)
HR (2) HRP20030806B1 (da)
HU (2) HU228106B1 (da)
IL (2) IL158246A0 (da)
IS (2) IS6965A (da)
MX (2) MXPA03008739A (da)
MY (3) MY145703A (da)
NO (2) NO20034437L (da)
NZ (2) NZ528598A (da)
PE (1) PE20020972A1 (da)
PL (2) PL208109B1 (da)
PT (2) PT1384726E (da)
SG (1) SG161737A1 (da)
SI (2) SI1411064T1 (da)
SK (2) SK287783B6 (da)
UA (3) UA75393C2 (da)
UY (2) UY27242A1 (da)
WO (2) WO2002081496A2 (da)
ZA (2) ZA200307585B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297336B2 (en) * 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
CN101111260B (zh) * 2005-02-04 2013-03-20 萨瓦克公司 存活蛋白肽疫苗
FI20055398A0 (fi) 2005-07-08 2005-07-08 Suomen Punainen Risti Veripalv Menetelmä solupopulaatioiden evaluoimiseksi
EP2594591B1 (en) * 2005-08-11 2018-06-06 Arpi Matossian-Rogers Tcr-v-beta related peptides for treatment and diagnosis of autoimmune disease
JP5415071B2 (ja) * 2005-08-19 2014-02-12 ワイス・エルエルシー Ｇｄｆ−８に対するアンタゴニスト抗体ならびにａｌｓおよびその他のｇｄｆ−８関連障害の処置における使用
ITFI20060163A1 (it) * 2006-06-29 2006-09-28 Menarini Internat Operations Luxembourg Sa Composizione farmaceutica contenente un anticorpo monoclonale anti idiotipico anti-ca-125 ed alluminio
TWI434855B (zh) 2006-11-21 2014-04-21 Hoffmann La Roche 結合物及其在免疫分析中作為參考標準之用途
WO2009104649A1 (ja) * 2008-02-22 2009-08-27 片山化学工業株式会社 合成糖脂質含有リポソーム
EP2166085A1 (en) 2008-07-16 2010-03-24 Suomen Punainen Risti Veripalvelu Divalent modified cells
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
NZ594985A (en) * 2009-03-10 2013-07-26 Biogen Idec Inc Anti-bcma (b-cell maturation antigen, cd269, tnfrsf17) antibodies
SG174992A1 (en) 2009-04-01 2011-11-28 Genentech Inc Anti-fcrh5 antibodies and immunoconjugates and methods of use
CU23736A1 (es) * 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
WO2011026242A1 (en) * 2009-09-03 2011-03-10 Vancouver Biotech Ltd. Monoclonal antibodies against gonadotropin-releasing hormone receptor
WO2012096994A2 (en) * 2011-01-10 2012-07-19 Emory University Antibodies directed against influenza
CU24070B1 (es) * 2011-12-27 2015-01-29 Ct De Inmunología Molecular Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
EP2641916A1 (en) * 2012-03-23 2013-09-25 Centre National de la Recherche Scientifique (C.N.R.S) Novel antibodies anti-sPLA2-IIA and uses thereof
MY177331A (en) 2012-06-15 2020-09-12 Pfizer Improved antagonist antibodies against gdf-8 and uses therefor
AR096687A1 (es) 2013-06-24 2016-01-27 Genentech Inc Anticuerpos anti-fcrh5
UA120753C2 (uk) 2013-12-17 2020-02-10 Дженентек, Інк. Біспецифічне антитіло до сd3 та cd20
JP2017512759A (ja) * 2014-04-10 2017-05-25 オービーアイ ファーマ インコーポレイテッド 抗体、前記抗体を産生するハイブリドーマ、前記抗体を含む薬学的組成物及びその用途
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
CA2986928A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. Humanized and affinity matured antibodies to fcrh5 and methods of use
WO2018017864A2 (en) * 2016-07-20 2018-01-25 Oncomed Pharmaceuticals, Inc. Pvrig-binding agents and uses thereof
CA3044664C (en) 2016-11-30 2022-11-22 Oncomed Pharmaceuticals, Inc. Methods for treatment of cancer comprising tigit-binding agents
CU20170173A7 (es) * 2017-12-27 2019-11-04 Ct Inmunologia Molecular Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2754206B2 (ja) * 1987-11-17 1998-05-20 メクト株式会社 α２→３結合を認識するモノクローナル抗体
US6051225A (en) * 1988-10-19 2000-04-18 The Dow Chemical Company Family of high affinity, modified antibodies for cancer treatment
EP0586002B1 (en) * 1992-08-18 2000-01-19 CENTRO de IMMUNOLOGIA MOLECULAR Monoclonal antibodies recognizing the epidermal growth factor receptor, cells and methods for their production and compositions containing them
JPH07101999A (ja) * 1993-10-06 1995-04-18 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体に対する抗イデイオタイプ抗体のアミノ酸配列およびそれをコードするｄｎａ塩基配列
US6063379A (en) * 1993-12-09 2000-05-16 Centro De Inmunologia Molecular Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies
CU22702A1 (es) * 1997-10-21 2001-07-31 Centro Inmunologia Molecular Anticuerpos monoclonales anti - idiotipo, su uso en la inmunoterapia activa de tumores malignos, hibridoma que los produce y composiciones que los contienen
EP0657471B1 (en) * 1993-12-09 2001-10-24 Centro de Inmunologia Molecular Anti ganglioside monoclonal antibodies and their use in the specific active immunotherapy of malignant tumours
CU22420A1 (es) * 1993-12-29 1996-01-31 Centro Inmunologia Molecular Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
US6149921A (en) * 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CU22731A1 (es) * 1998-02-05 2002-02-28 Centro Inmunologia Molecular Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies

Also Published As

Publication number Publication date
CA2441845C (en) 2011-06-07
NO20034436L (no) 2003-12-02
EA006936B1 (ru) 2006-06-30
ATE406386T1 (de) 2008-09-15
SK12262003A3 (sk) 2004-08-03
UA76745C2 (uk) 2006-09-15
BR0208676A (pt) 2008-04-08
CU23007A1 (es) 2004-12-17
WO2002081496A3 (es) 2004-02-19
KR100863509B1 (ko) 2008-10-15
NO331533B1 (no) 2012-01-23
DE60223547T2 (de) 2008-09-18
CZ20032668A3 (cs) 2004-07-14
KR20030092048A (ko) 2003-12-03
BG108227A (bg) 2005-04-30
SK12162003A3 (sk) 2004-05-04
NO20034437D0 (no) 2003-10-03
UY27242A1 (es) 2002-07-31
NZ528598A (en) 2005-03-24
CN101054417A (zh) 2007-10-17
MY157372A (en) 2016-06-15
SI1384726T1 (sl) 2009-04-30
KR20080080680A (ko) 2008-09-04
DK1411064T3 (da) 2008-03-25
CA2441845A1 (en) 2002-10-17
CN1535282A (zh) 2004-10-06
AU2002308347B2 (en) 2006-09-14
MY137078A (en) 2008-12-31
EP1798243A2 (en) 2007-06-20
BRPI0208675B1 (pt) 2018-03-13
KR100919617B1 (ko) 2009-09-29
CN1319991C (zh) 2007-06-06
DE60223547D1 (de) 2007-12-27
EA200301097A1 (ru) 2004-02-26
NO20034436D0 (no) 2003-10-03
PL208109B1 (pl) 2011-03-31
CZ20032641A3 (cs) 2004-07-14
HK1070080A1 (en) 2005-06-10
NZ528599A (en) 2005-03-24
US20050069535A1 (en) 2005-03-31
SK287783B6 (sk) 2011-09-05
JP2004528033A (ja) 2004-09-16
IL158246A (en) 2010-05-31
IS2701B (is) 2010-11-15
IL158246A0 (en) 2004-05-12
EA006310B1 (ru) 2005-10-27
ATE477279T1 (de) 2010-08-15
HUP0401695A3 (en) 2012-05-29
IS6964A (is) 2003-09-23
EA200301098A1 (ru) 2004-04-29
JP4366080B2 (ja) 2009-11-18
AU2007231687B2 (en) 2010-09-30
CZ304424B6 (cs) 2014-04-30
EP1411064A2 (en) 2004-04-21
BR0208676B1 (pt) 2017-11-14
EP1411064B1 (en) 2007-11-14
NO20034437L (no) 2003-12-02
CN101054417B (zh) 2012-07-11
AR033122A1 (es) 2003-12-03
ECSP034787A (es) 2004-01-28
PT1411064E (pt) 2008-02-12
WO2002081496A2 (es) 2002-10-17
AR033123A1 (es) 2003-12-03
AU2007231687A1 (en) 2007-11-22
DE60228561D1 (de) 2008-10-09
IS6965A (is) 2003-09-23
MXPA03008739A (es) 2003-12-11
UY27243A1 (es) 2002-09-30
MXPA03008738A (es) 2003-12-11
EP1798243A3 (en) 2007-10-17
CN100349920C (zh) 2007-11-21
HUP0401355A2 (hu) 2004-10-28
EP1798243B1 (en) 2010-08-11
HRP20030806B1 (en) 2011-11-30
BG108228A (bg) 2005-04-30
PL371770A1 (en) 2005-06-27
BG66293B1 (en) 2013-02-28
CA2443372C (en) 2013-05-28
MY145703A (en) 2012-03-30
CZ296276B6 (cs) 2006-02-15
US20100297008A1 (en) 2010-11-25
PT1384726E (pt) 2008-12-05
US20040253233A1 (en) 2004-12-16
ZA200307585B (en) 2004-09-16
SG161737A1 (en) 2010-06-29
SI1411064T1 (sl) 2008-04-30
HK1066818A1 (da) 2005-04-01
WO2002081661A3 (es) 2003-01-03
UA75393C2 (en) 2006-04-17
HUP0401695A2 (en) 2006-08-28
JP2004525953A (ja) 2004-08-26
HK1109160A1 (en) 2008-05-30
HU228106B1 (en) 2012-11-28
HRP20030805B1 (en) 2011-11-30
ZA200307679B (en) 2005-03-30
KR100946168B1 (ko) 2010-03-11
HUP0401355A3 (en) 2012-05-29
EP1384726A2 (en) 2004-01-28
US8758753B2 (en) 2014-06-24
HU228105B1 (en) 2012-11-28
ES2312610T3 (es) 2009-03-01
EP1384726B1 (en) 2008-08-27
ES2296986T3 (es) 2008-05-01
AU2002308348B2 (en) 2007-11-22
HRP20030806A2 (en) 2005-08-31
HRP20030805A2 (en) 2005-08-31
ATE378356T1 (de) 2007-11-15
BR0208675A (pt) 2004-08-03
PL371937A1 (en) 2005-07-11
SK287914B6 (sk) 2012-03-02
BG66304B1 (bg) 2013-03-29
UA86768C2 (ru) 2009-05-25
CN1507452A (zh) 2004-06-23
PE20020972A1 (es) 2003-01-02
KR20030087053A (ko) 2003-11-12
WO2002081661A2 (es) 2002-10-17
CA2443372A1 (en) 2002-10-17
ECSP034788A (es) 2004-01-28

Similar Documents

Publication Publication Date Title
DK1384726T3 (da) Immunoterapeutiske kombinationer til behandling af tumorer, der overudtrykker gangliosider
DE60131534D1 (de) Umfassender Authentifizierungsmechanismus
DE60143856D1 (de) Sonos-bauelementeisolation
DK1303478T3 (da) Fremgangsmåde til fremstilling af substituerede octanoylamider
DE60310731D1 (de) Neue, von noraporphin abgeleitete moleküle
DE60210160D1 (de) Snowboardbindung
DE60323182D1 (de) Authentifizierungssystem
IS7243A (is) C-5 breytt indazólýlpýrrólótríazín
DK1277722T3 (da) Fremgangsmåde til fremstilling af methanol
DK1542725T3 (da) Fremgangsmåde til humanisering af immunsystemsmolekyler
AT503097A3 (de) Snowboardbindung
DK1395957T3 (da) Dualt vejafgiftssystem
DK1499730T3 (da) Immunokonjugater til behandling af tumorer
DE60328345D1 (de) Skibindung
NO20034921D0 (no) Skibinding
DE50303965D1 (de) Skibindung, insbesondere touren-, telemark- oder langlaufbindung
DK1350521T3 (da) Immunoterapeutiske kombinationer til behandling af tumorer
DK1399016T3 (da) Fremgangsmåde til generering af diversitet
DE60217780D1 (de) Skischuh
DK1395587T3 (da) Fremgangsmåde til fremstilling af imipenem
DE50205399D1 (de) Schlitzstrahlerelement
DE50213389D1 (de) Skibindung
DE60207467D1 (de) Snowboardbindung
DK1349850T3 (da) Natriumkanalmodulatorer, der er afledt af 2-piperidylimidazoler
ATA1712001A (de) Snowboardbindung